Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- Haysmed
Hays, Kansas, United States
- Lawrence Memorial Hospital
Lawrence, Kansas, United States
- the University of Kansas Cancer Center - Olathe
Olathe, Kansas, United States
- University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
- Mercy Hospital Pittsburg
Pittsburg, Kansas, United States
- Salina Regional Health Center
Salina, Kansas, United States
- University of Kansas Health System Saint Francis Campus
Topeka, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- University Health Truman Medical Center
Kansas City, Missouri, United States
- University of Kansas Cancer Center - North
Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
- University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, United States
- Wake Forest University at Clemmons
Clemmons, North Carolina, United States
- Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Nov 2020
- Primary completion
- 1 Jul 2024
- Completion
- 28 Jan 2027
- Last update posted
- 13 Apr 2026
- Registered enrollment
- 17
- Registry id
- NCT03641313
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.